Last Price
0.78
Today's Change
-0.045 (5.45%)
Day's Change
0.77 - 0.815
Trading Volume
616,214
Overview
Market Cap
960 Million
Shares Outstanding
1 Billion
Avg Volume
5,032,121
Avg Price (50 Days)
0.78
Avg Price (200 Days)
0.60
PE Ratio
-1.47
EPS
-0.53
Earnings Announcement
26-Feb-2025
Previous Close
0.82
Open
0.81
Day's Range
0.77 - 0.815
Year Range
0.32 - 0.955
Trading Volume
616,214
Price Change Highlight
1 Day Change
-5.45%
5 Day Change
-3.11%
1 Month Change
-14.29%
3 Month Change
85.71%
6 Month Change
14.71%
Ytd Change
38.05%
1 Year Change
136.36%
3 Year Change
-36.07%
5 Year Change
-74.84%
10 Year Change
392.61%
Max Change
241.44%
News and Blogs
No result.
Company Profile
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema (DME), as well as a first in class VEGF-C/D inhibitors for treatment with VEGF-A inhibitors to treat wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.
Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment
Apps
Top Articles
1
CEO Morning Brief
Australia Faces Economic Pain From Trump Win, Treasurer Warns
2
CEO Morning Brief
#
Stock
Score
Daily Stocks
Stock
Last
Change
Volume
Ride The Bull Short The Bear
CS Tan
4.9 / 5.0
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
